Speed of PSA rise helps predict survival for prostate cancer patients
Posted on: Friday, 30 September 2005, 17:09 CDT
The clinical outcome for prostate cancer patients who have been treated with hormone therapy and radiation therapy can usually be determined by how rapidly their prostate specific antigen level rises following treatment, according to a report published in the October 1, 2005 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.
Doctors at M.D. Anderson Cancer Center in Houston studied 621 men with prostate cancer treated with hormone and radiation therapy between 1989 and 2003 to determine whether clinical failure after their treatment correlated with the speed at which their post treatment PSA level rose. Clinical failure was defined as cancer recurring in the prostate or spreading to other parts of the body.
Researchers found that measuring how quickly the PSA level doubled was a good indicator of subsequent poor clinical outcomes, including cancer developing in other parts of the body or death related to prostate cancer.
Patients whose PSA level doubled within eight months after treatment failure were more likely to have the cancer return or spread to other parts of the body than patients whose PSA did not double in eight months or less. The estimated five-year rate of clinical failure for patients with a PSA doubling time of more than eight months was only 9.4 percent while 60.4 percent of patients whose PSA doubling time was less than or equal to eight months could expect some type of clinical failure.
"The PSA doubling time is an important indicator of how well a patient will recover from prostate cancer," said Andrew K. Lee, M.D., lead author of the study and a radiation oncologist at M.D. Anderson Cancer Center in Houston. "Although clinical outcomes may be positively affected if the patient receives hormone therapy with radiation therapy, a quickly rising PSA level unfortunately still portends poor results for these patients."
On the World Wide Web:
American Society for Therapeutic Radiology and Oncology
Related Articles
- Sirtex Supports the Fourth Annual Clinical Symposium on Liver-Directed Microsphere Therapy Dedicated to Advancing Treatments for Patients With Inoperable Metastatic Liver Cancer
- Screening Tests May Miss Prostate Cancer in Obese Patients
- Affymax(R) Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide(TM) for the Treatment of Anemia
- CoGenesys Initiates Phase 1-2 Clinical Trial of Cardeva in Patients With Heart Failure
- Balance Rehabilitation Honors National Physical Therapy Month By Hosting an Educational Open House for Community
- New Hope For Prostate Cancer Patients Where Radiation Treatment Has Failed
- Radiation and Hormone Therapy After Surgery Cures Breast Cancer, Says ASTRO
- PSA increase predicts prostate cancer outcome
- EMSYS Corporation Files A Patent Application For Its Patient Specific Radiation Therapy Billing System
- Amgen Announces Initiation of Phase 3 Trial to Evaluate the Impact of Treating Anemia With Darbepoetin Alfa in Patients With Heart Failure to Reduce Mortality and Hospitalization
 |
 |
User Comments (0)
RSS Feeds